Next, the implications of loss or upregulation of Cav-1 in ECs in various pathological conditions such as pulmonary hypertension, cardiac hypertrophy, acute lung injury, atherosclerosis, ischemia, or pathological angiogenesis associated with cancer and inflammation will be discussed (Figure 1). This evidence concerns the gene CAV1 and pulmonary hypertension.